GPS Wealth Strategies Group LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 191.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 175 shares of the medical research company’s stock after purchasing an additional 115 shares during the quarter. GPS Wealth Strategies Group LLC’s holdings in Thermo Fisher Scientific were worth $103,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently made changes to their positions in TMO. Karp Capital Management Corp lifted its position in shares of Thermo Fisher Scientific by 0.5% in the fourth quarter. Karp Capital Management Corp now owns 3,195 shares of the medical research company’s stock worth $2,132,000 after purchasing an additional 17 shares in the last quarter. Archer Investment Corp increased its holdings in Thermo Fisher Scientific by 1.3% in the fourth quarter. Archer Investment Corp now owns 1,317 shares of the medical research company’s stock worth $879,000 after buying an additional 17 shares during the last quarter. Deseret Mutual Benefit Administrators increased its holdings in Thermo Fisher Scientific by 2.7% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 647 shares of the medical research company’s stock worth $432,000 after buying an additional 17 shares during the last quarter. Mechanics Bank Trust Department increased its holdings in Thermo Fisher Scientific by 0.9% in the fourth quarter. Mechanics Bank Trust Department now owns 1,963 shares of the medical research company’s stock worth $1,310,000 after buying an additional 18 shares during the last quarter. Finally, Cadence Bank NA increased its holdings in Thermo Fisher Scientific by 0.3% in the first quarter. Cadence Bank NA now owns 7,050 shares of the medical research company’s stock worth $4,164,000 after buying an additional 18 shares during the last quarter. Institutional investors and hedge funds own 87.48% of the company’s stock.
In other Thermo Fisher Scientific news, Director Debora L. Spar sold 200 shares of Thermo Fisher Scientific stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $544.36, for a total transaction of $108,872.00. Following the completion of the transaction, the director now directly owns 810 shares of the company’s stock, valued at $440,931.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $545.60, for a total value of $5,456,000.00. Following the transaction, the chief executive officer now directly owns 183,373 shares of the company’s stock, valued at $100,048,308.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 42,561 shares of company stock valued at $23,557,413. 0.43% of the stock is owned by company insiders.
Several brokerages have commented on TMO. StockNews.com began coverage on Thermo Fisher Scientific in a report on Thursday, March 31st. They set a “hold” rating on the stock. Wells Fargo & Company downgraded Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $605.00 to $525.00 in a report on Monday, April 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $658.92.
TMO opened at $548.27 on Friday. The stock has a market capitalization of $214.63 billion, a price-to-earnings ratio of 28.59, a P/E/G ratio of 1.85 and a beta of 0.83. Thermo Fisher Scientific Inc. has a 1-year low of $497.83 and a 1-year high of $672.34. The business has a 50-day moving average of $539.82 and a 200-day moving average of $570.71. The company has a current ratio of 1.56, a quick ratio of 1.10 and a debt-to-equity ratio of 0.77.
Thermo Fisher Scientific (NYSE:TMO – Get Rating) last issued its earnings results on Thursday, April 28th. The medical research company reported $7.25 EPS for the quarter, topping the consensus estimate of $6.17 by $1.08. The firm had revenue of $11.82 billion during the quarter, compared to analysts’ expectations of $10.66 billion. Thermo Fisher Scientific had a return on equity of 25.33% and a net margin of 18.49%. Thermo Fisher Scientific’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same period last year, the business earned $7.21 earnings per share. Equities analysts predict that Thermo Fisher Scientific Inc. will post 22.7 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, July 15th. Investors of record on Wednesday, June 15th will be given a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, June 14th. This represents a $1.20 annualized dividend and a yield of 0.22%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 6.26%.
Thermo Fisher Scientific Profile: (Get Rating)
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating).
Receive News & Ratings for Thermo Fisher Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.